Thema: US98943L1070
ZNTL, US98943L1070
chart-1905225_1920.jpg - Foto: THN
Zentalis Pharmaceuticals stock: azenosertib data sharpen biomarker case
Zentalis Pharmaceuticals stock remains in focus after new azenosertib survival data. The results strengthen the case for biomarker-led development.
ad-hoc-news.de, heute 00:41 Uhr
ZNTL, US98943L1070
Zentalis published survival data for Zentalis Pharmaceuticals ...
Zentalis reported 15.8 months of median survival on October 18, 2026. Zentalis Pharmaceuticals stock has a presentation on October 23, 2026.
ad-hoc-news.de, 21.10.26 06:42 Uhr
ZNTL, US98943L1070
Leerink raised its target to USD 8 for Zentalis Pharmaceuticals ...
Zentalis reported a USD 0.59 GAAP loss per share in the second quarter. Zentalis Pharmaceuticals stock has data dates on October 23 and October 26.
ad-hoc-news.de, 16.10.26 00:32 Uhr
ZNTL, US98943L1070
Zentalis Pharmaceuticals stock gains 10.32 percent after ...
Zentalis Pharmaceuticals stock last traded at USD 2.78 on October 5, 2026, after Leerink set an USD 8.00 target. Q2 EPS missed consensus.
ad-hoc-news.de, 06.10.26 14:51 Uhr
ZNTL, US98943L1070
Wells Fargo sets USD 5.00 target for Zentalis Pharmaceuticals ...
Zentalis posted a USD 77.64 million GAAP loss in Q2 2026. For Zentalis Pharmaceuticals stock, market value stood at USD 185.4 million on October 1, 2026.
ad-hoc-news.de, 02.10.26 02:55 Uhr
